Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932828 · ClinicalTrials.gov registry record · Phase 2
Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT00932828 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 37 participants.
The verdict
NCT00932828, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-specific immune response in subjects who have peanut allergy (tolerance).
Interventions
- DRUG Peanut oral immunotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-06-22 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932828
The ClinicalTrials.gov registry entry for NCT00932828 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Peanut oral immunotherapy is the first listed.
NCT00932828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932828 about?
NCT00932828 is a clinical study titled "Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study". Peanut allergy is known to cause severe anaphylactic reactions.The goal of this proposal is to produce a new treatment that would benefit young subjects who have recently been diagnosed with peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing the peanut-spec...
What is the current status of trial NCT00932828?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2009-06-22. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT00932828?
The interventions under investigation include: Peanut oral immunotherapy (DRUG).
Who is sponsoring clinical trial NCT00932828?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.